Safety and Immunogenicity of Two Acellular Pertussis Vaccines with Different Pertussis Toxoid and Filamentous Hemagglutinin Content in Infants 2-6 Months Old

References

• Centers for Disease Control. Summary of notifiable diseases, United States, 1991. MMWR 1991; 40: 35–36, 57-63
   Google Scholar
• Varughese P. Incidence of pertussis in Canada. Can Med Assoc J 1985; 132: 1041–1042
   PubMedGoogle Scholar
• Cherry J. D., Brunell P. A., Golden G. S., Karzon D. T. Report of the task force on pertussis and pertussis immunization - 1988. Pediatrics 1988; 81(suppl)939–984
   Google Scholar
• Cherry J. D. The epidemiology of pertussis and pertussis immunization in the United States: a comparative study. Curr Probl Pediatr 1984; 14: 1–78
   PubMedGoogle Scholar
• Romanus V., Jonsell R., Bergquist S. O. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987; 6: 364–371
   PubMed Web of Science ®Google Scholar
• Sato H., Sato Y. Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun 1984; 46: 415–421
   PubMedGoogle Scholar
• Oda M., Cowell J. L., Burstyn D. G., Manclark C. R. Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J Infect Dis 1984; 150: 823–833
   PubMed Web of Science ®Google Scholar
• Aoyama T., Murase Y., Kato M., Iwai H., Iwata T. Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age. Am J Dis Child 1989; 143: 655–659
   PubMedGoogle Scholar
• Mortimer E. A., Jr., Kimura M., Cherry J. D., Kuno-Sakai H., Stout M. G., Dekker C. L., Hayashi R., Miyamoto Y., Scott J. V., Aoyama T., Isomura S., Iwata T., Kamiya H., Kato T., Noya J., Suzuki E., Takeuchi Y., Yamaoka H. Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am J Dis Child 1990; 144: 899–904
   PubMedGoogle Scholar
• Ad Hoc Group for the Study of Pertussis Vaccines. Placebocontrolled trial of two acellular pertussis vaccines in Sweden protective efficacy and adverse events. Lancet 1988; i: 955–960
   Google Scholar
• Brennan M. J., Li Z. M., Cowell J. L., Bisher M. E., Steven A. C., Novotny P., Manclark C. R. Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infect Immun 1988; 56: 3189–3195
   PubMedGoogle Scholar
• Zhang J. M., Cowell J. L., Steven A. C., Carter P. H., McGrath P. P., Manclark C. R. Purification and characterization of fimbriae isolated from Bordetella pertussis. Infect Immun 1985; 48: 422–427
   PubMedGoogle Scholar
• Li Z. M., Brennan M. J., David J. L., Carter P. H., Cowell J. L., Manclark C. R. Comparison of type 2 and type 6 fimbriae of Bordetella pertussis by using agglutinating monoclonal antibodies. Infect Immun 1988; 56: 3184–3188
   PubMedGoogle Scholar
• Shahin R. D., Brennan M. J., Li Z. M., Meade B. D., Manclark C. R. Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med 1990; 171: 63–73
   PubMed Web of Science ®Google Scholar
• Roberts M., Tite J. P., Fairweather N. F., Dougan G., Charles I. G. Recombinant P. 69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection. Vaccine 1992; 10: 43–48
   PubMedGoogle Scholar
• Podda A., Nencioni L., Marsili I., Peppoloni S., Volpini G., Donati D., Di Tommaso A., De Magistris M. T., Rappuoli R. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69kDa. Vaccine 1991; 9: 741–745
   PubMedGoogle Scholar
• Miller E., Ashworth L. AE, Robinson A., Waight P. A., Irons L. I. Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens. Lancet 1991; 337: 70–73
   PubMed Web of Science ®Google Scholar
• Glode M., Joffe L., Reisinger K., Blatter M., Plotkin S., Watson B., Grossman L., Asmar B., Berry M., Starobin S., Fisch G., Hackell J. G., Sheip B., McKee BSafety, The Children's Medical Center, Pennridge Pediatric Associates. and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17-to 24-month-old children. Pediatr Infect Dis J 1992; 11: 530–535
   PubMedGoogle Scholar
• Blumberg D. A., Mink C. M., Cherry J. D., Johnson C., Garber R., Plotkin S. A., Watson B., Ballanco G. A., Daum R. S., Sullivan B., Townsend T. R., Brayton J., Gooch W. M., III, Nelson D. B., Congeni B. L., Prober C. G., Hackell J. G., Dekker C. L., Christenson P. D., APDT Vaccine Study Group. Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-petussis vaccines in infants. J Pediatr 1991; 119: 194–204
   PubMed Web of Science ®Google Scholar
• Halperin S. A., Barreto L., Friesen B., Meekison W. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children. Arch Pediatr Adolesc Med 1994; 148: 495–502
   PubMed Web of Science ®Google Scholar
• Halperin S. A., Barreto L., Eastwood B. J., Law B., Roberts E. A. Safety and immunogenicity of a five-component acellular pertussis vaccine with varying antigen quantities. Arch Pediatr Adolesc Med 1994; 148: 1220–1224
   PubMedGoogle Scholar
• Manclark C. R., Meade B. D., Burstyn D. G. Serological response to Bordetella pertussis. Manual of Clinical Laboratory Immunology, 3rd edn., N. R. Rose, H. Friedman, J. L. Fahey. American Society for Microbiology, Washington, DC 1986; 388–394
   Google Scholar
• Gillenius P., Jäätmaa E., Askelöf P., Granström M., Tiru M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J Biol Stand 1984; 13: 61–66
   Google Scholar
• Breslow N. E., Day N. E. Statistical Methods in Cancer Research, vol. II. The Design and Analysis of Cohort Studies. International Agency for Research on Cancer, LyonsFrance 1987; 108–113
   Google Scholar
• Cody C. L., Baraff L. J., Cherry J. D., Marcy S. M., Manclark C. R. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981; 68: 650–660
   PubMed Web of Science ®Google Scholar
• Long S. S., Deforest A., Pennridge Pediatric Associates, Smith D. G., Lazaro C., Wassilak S. GF. Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy. Pediatrics 1990; 85: 294–302
   PubMed Web of Science ®Google Scholar
• National Advisory Committee on Immunization (NACI). Statement on pertussis immunization. Can Commun Dis Rep 1993; 19: 41–45
   PubMedGoogle Scholar
• Committee to Review the Adverse Consequences of Pertussis and Rubella Vaccines. Shock and “unsual shock-like state” with hypotonicity, hyporesponsiveness, and short-lived convulsions, usually febrile. Adverse Effects of Pertussis and Rubella Vaccines, C. P. Howson, C. J. Howe, H. V. Fineberg. National Academy Press, Washington, DC 1991; 171–177
   Google Scholar
• Blumberg D. A., Mink C. M., Lewis K., Chatfield P., Leach C., Smith L. P., Christenson P. D., Guravita L., Steinfeld M. BJ, March S. M., Levin S. R., Baraff L. J., Schonfeld N., Cherry J. D. Pathopbysiology of reactions associated with pertussis vaccine. Dev Biol Stand 1990; 73: 289–295
   Google Scholar
• Medical Research Council. The prevention of whooping cough by vaccination. BMJ 1951; 1: 1463–1471
   PubMedGoogle Scholar
• Novotny P., Kobisch M., Cownley K., Chubb A. P., Montaraz J. A. Evaluation of Bordetella bronchiseptica vaccines in specific-pathogen-free piglets with bacterial cell surface antigen in enzyme-linked immunosorbent assay. Infect Immun 1985; 50: 190–198
   PubMedGoogle Scholar
• Kobisch M., Novotny P. Identification of a 68-kilodalton outer membrane protein as the major protective antigen of Bordetella bronchiseptica by using specific-pathogen-free piglets. Infect Immun 1990; 58: 352–357
   PubMed Web of Science ®Google Scholar
• Moxon E. R., Rappuoli R. Haemophilus influenzae infections and whooping cough. Lancet 1990; 335: 1324–1329
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use - supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1992; 41(No. RR-1)1–10
   Google Scholar
• Committee on Infectious Diseases - American Academy of Pediatrics. Acellular pertussis vaccines: recommendations for use as the fourth and fifth doses. Pediatrics 1992; 90: 121–123
   PubMedGoogle Scholar
• Englund J. A., Decker M. D., Edwards K. M., Pichichero M. E., Steinhoff M. C., Anderson E. L. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics 1994; 93: 37–43
   PubMed Web of Science ®Google Scholar
• Sekura R. D., Zhang Y., Roberson R., Acton B., Trollfors B., Tolson N., Shiloach J., Bryla D., Muir-Nash J., Koeller D., Schneerson R., Robbins J. B. Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide. J Pediatr 1988; 113: 806–813
   Google Scholar
• Krantz I., Sekura R., Trollfors B., Taranger J., Zackrisson G., Lagergård T., Schneerson R., Robbins J. Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide, in 18- to 23-month-old children. J Pediatr 1990; 116: 539–543
   Google Scholar
• Siber G. R., Thakrar N., Yancey B. A., Herzog L., Todd C., Cohen N., Sekura R. D., Lowe C. U. Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children. Vaccine 1991; 9: 735–740
   PubMedGoogle Scholar